Search

Yuhan Liu,1,* Anbang He,1,2,* Baoer Liu,1 Yucheng Zhong,1 Xinhui Liao,1 Jiangeng Yang,1 Jieqing Chen,1 Jianting Wu,1 Hongbing Mei1 1Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China; 2Department of Urology, Peking University First Hospital, The Institute of Urology, Peking University, National Urological Cancer Centre, Beijing, China *These authors contributed equally to this work Abstract: Several epidemiological studies have reported that polymorphisms in microRNA-196a2 (miR-196a2) were associated with various cancers. However, the results remained unverified and were inconsistent in different cancers. Therefore, we carried out an updated meta-analysis to elaborate the effects of rs11614913 polymorphism on cancer susceptibility. A total of 84 articles with 35,802 cases and 41,541 controls were included to evaluate the association between the miR-196a2 rs11614913 and cancer risk by pooled odds ratios (ORs) and 95% confidence intervals (CIs). The results showed that miR-196a2 rs11614913 polymorphism is associated with cancer susceptibility, especially in lung cancer (homozygote comparison, OR =0.840, 95% CI=0.734–0.961; recessive model, OR =0.858, 95% CI =0.771–0.955), hepatocellular carcinoma (allelic contrast, OR=0.894, 95% CI=0.800–0.998; homozygote comparison, OR=0.900, 95% CI =0.813–0.997; recessive model, OR=0.800, 95% CI=0.678–0.944), and head and neck cancer (allelic contrast, OR=1.076, 95% CI=1.006–1.152; homozygote comparison, OR=1.214, 95% CI=1.043–1.413). In addition, significant association was found among Asian populations (allele model, OR=0.847, 95% CI=0.899–0.997, P=0.038; homozygote model, OR=0.878, 95% CI=0.788–0.977,P=0.017; recessive model, OR=0.895, 95% CI=0.824–0.972,P=0.008) but not in Caucasians. The updated meta-analysis confirmed the previous results that miR-196a2 rs11614913 polymorphism may serve as a risk factor for patients with cancers. Keywords: miR-196a2, polymorphisms, cancer risk, meta-analysis

This study was a meta-analysis of the literature on the efficacy and safety of tenofovir disoproxil fumarate (TDF) in preventing vertical transmission of hepatitis B in pregnancies with high viral load. Four observational studies and one randomized controlled trial involving 585 pregnant women and 595 newborns were included in the meta-analysis. TDF was more effective than the placebo in reducing vertical transmission in HBeAg-positive chronic hepatitis B (CHB) pregnancies with high serum HBV-DNA levels (OR = 0.21, 95% CI = 0.07–0.61) at 4–12 months, infant HBV DNA seropositivity at delivery (OR = 0.16, 95% CI = 0.07–0.37), and a severe flair in maternal alanine aminotransferase (ALT) levels (OR = 0.43, 95% CI = 0.19–0.95) during pregnancy. In addition, TDF showed more improvement in HBV DNA suppression at delivery (OR = 254.46, 95% CI = 28.39–2280.79). No significant differences were found in HBeAg seroconversion or ALT normalization; or in rates of cesarean section, emergent cesarean section, postpartum hemorrhage, prematurity, congenital malformations, or infant death. However, TDF induced more drug-related adverse events (OR = 2.33, 95% CI = 1.39–3.89) and elevated creatine kinase (CK) (OR = 9.56, 95% CI = 1.17–78.09) than in controls. The available evidence suggests that TDF is effective and safe in preventing vertical transmission of hepatitis B in pregnancies exhibiting a high viral load.